Upsher-Smith Laboratories is a U.S. pharmaceutical company (now a subsidiary of Bora Pharmaceuticals following a $210 million acquisition in April 2024) that manufactures and markets brand and generic pharmaceutical products. It has a 270,000 sq ft manufacturing facility in Plymouth/Maple Grove, Minnesota. Key products include branded medications for migraine and seizure disorders plus a wide variety of generics (48 products). In December 2025 it launched KYMBEE (deflazacort) for Duchenne muscular dystrophy. While Bora Pharmaceuticals is a CDMO, Upsher-Smith itself manufactures and markets its own branded/generic portfolio rather than providing contract manufacturing services to third parties.
branded pharmaceuticals (migraine, epilepsy), generic pharmaceuticals, oral solid dose manufacturing, rare disease (DMD)
1 site worldwide
No reviews available yet.
No documents available.